ClinicalTrials.gg
CompletedNCT04907682SAFARIUpdated Feb 8, 2023

Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever

A Phase 2 interventional study of Ribavirin iv and Favipiravir in Lassa Fever, sponsored by Bernhard Nocht Institute for Tropical Medicine. Completed at 2 sites in Nigeria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Bernhard Nocht Institute for Tropical Medicine · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa fever (LF), with the current standard of care, ribavirin.

The primary endpoints of this research are (1) the description of classical pharmacokinetic parameters of favipiravir in comparison with ribavirin standard treatment in patients suffering from LF and (2) the safety and tolerability of both study drugs in the investigated regimens.

Read the detailed description

The currently used antiviral for the treatment of LF, which is also recommended by the World Health Organization (WHO) and the Nigeria Center for Disease Control, is ribavirin. However, evidence for ribavirin efficacy in LF patients adds up to the results of a single study with serious limitations. A promising new treatment candidate that showed efficacy against LF in preclinical studies is Favipiravir. It has further been evaluated for the treatment of Ebola Virus disease during the West-African Ebola outbreak and is approved for treatment of pandemic influenza virus infections in Japan.

The study will be conducted at two study sites in Nigeria: the Irrua Specialist Teaching Hospital (ISTH) and the Federal Medical Center of Owo (FMCO). Lassa fever patients of 18 years and older with LF confirmed by reverse-transcription polymerase chain reaction (RT-PCR) hospitalized at either ISTH or FMCO will be asked to participate in this study. A total of 40 evaluable participants will be randomized to two treatment arms (20 participants per arm): intravenous ribavirin standard of care treatment (Irrua regimen), oral favipiravir. Patients will be included in the study after giving written informed consent and if all inclusion criteria and no exclusion criteria are met. Multiple blood draws with the purpose of virologic, serologic and immunological analyses, hematological and biochemical analyses as well as pharmacokinetic analyses will be performed throughout the study duration of ten days. Adverse events (AEs), serious adverse events (SAEs) and pregnancy will be captured, monitored and followed-up. A medical monitor will be available for study investigators to assist with any clinical and safety related questions. An external data safety monitoring board (DSMB) will conduct periodic safety reviews.

Data will be captured on source documents and electronic case report forms (eCRFs). Informed consent forms will be stored in a lockable cabinet. Participants data will only be linked to the unique identifier to ensure pseudonymity.

Statistical analysis of study endpoints and pharmacokinetic parameters will be performed descriptively. Missing data will be treated as such, no imputation will be applied.

The study will be conducted in compliance with the protocol, the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guideline and the Nigerian National Code for Health Research Ethics, in particular concerning the submission to the ethics committees and the protection of personal data as well as other national and regulatory requirements.

02

Conditions studied

  • Lassa Fever

Keywords

  • Ribavirin
  • Favipiravir
  • viral hemorrhagic fever
03

In context

Hemorrhagic Fevers, Viral

38 studies on the registry are indexed under Hemorrhagic Fevers, Viral; 6 are open to participants now.

This study's enrollment of 40 is below the median of 98 across 29 interventional studies indexed under Hemorrhagic Fevers, Viral.

Browse Hemorrhagic Fevers, Viral studies →

Lead sponsor

Bernhard Nocht Institute for Tropical Medicine is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • LF confirmed by RT-PCR (reverse-transcription polymerase chain reaction)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Inability to give consent (e.g. unconscious patients/ cognitively impaired patients)
  • Pregnancy/lactation (evidenced by negative urine pregnancy test in women of )
  • Women who plan to get pregnant within the upcoming 6 months
  • Severe malnutrition (\<16)
  • Known intolerance to ribavirin or favipiravir
  • History of hemoglobinopathies (i.e., sickle-cell anaemia or thalassemia major) and/or haemophilia
  • Organ failure as evidenced by:

    • Creatinine ≥ 3x (ULN)
    • (AST/GOT) > 150 IU/l
    • Alert, confusion, voice, pain, unresponsive (ACVPU) score = V or P or U (corresponds to Glasgow Coma Scale (GCS) ≤ 12)
    • Severe central nervous system features (e.g. seizures, restlessness, confusion and coma)
    • O2 Saturation \< 90%
    • Hematocrit \<30 %
    • Severe anaemia requiring blood transfusion
  • Inability to take oral drug (e.g. encephalopathy, severe vomiting)
  • Patients who already received ribavirin or favipiravir within the preceding 7 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Intravenous ribavirin

    standard treatment: Irrua regimen * 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day) * 25 mg/kg days 2-7 * 12.5 mg/kg days 8-10

    Drug: Ribavirin iv

  • Experimental
    Oral favipiravir

    Oral favipiravir * Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16) * Day 2-10 1200mg twice daily (BD)

    Drug: Favipiravir

Interventions

  • DrugRibavirinStudies of RibavirinRibavirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10

    Also known as: Irrua regimen

  • Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily

    Also known as: Avigan

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter of favipiravir: Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) of favipiravir

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 7, Day 8 and Day 10 of the study conduct

  2. Pharmacokinetic parameter of favipiravir: Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) of favipiravir

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 7, Day 8 and Day 10 of the study conduct

  3. Pharmacokinetic parameter of favipiravir: Area under the concentration-time curve (AUC)

    Area under the concentration-time curve (AUC) of favipiravir

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 7, Day 8 and Day 10 of the study conduct

  4. Pharmacokinetic parameter of favipiravir: Half life (T1/2)

    Half life (T1/2) of favipiravir

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 7, Day 8 and Day 10 of the study conduct

  5. Proportion of drug related AEs and SAEs of both study treatments

    Safety and tolerability of ribavirin and favipiravir in investigated regimens by investigating the proportion of drug related AEs and SAEs

    Time frame: throughout study completion (10 days per participant)

Secondary outcomes

  1. Mutagenicity

    Mutagenicity of ribavirin and favipiravir measured via nucleotide exchange rate in individual Lassa virus genomes

    Time frame: 10 days

  2. Change from baseline in Viral RNA loads

    Description of viral loads during treatment Relative Lassa virus RNA concentrations in RNA copies per milliliters (RNA copies/ml).

    Time frame: Day of enrollment - Day 10

  3. Change from baseline in Lassa virus titers

    Description of infectious titers during treatment. Infectious titers expressed as focus forming units per milliliters or FFU/ml using immuno-focus assay for Lassa virus.

    Time frame: Day of enrollment - Day 10

  4. Change from baseline in Lassa virus serological status

    Description of antibody response during treatment. To evaluate the presence or absence of Lassa virus immunoglobulin M (IgM) and G (IgG) antibodies; qualitative results

    Time frame: 10 days

  5. Pharmacokinetic (PK) modelling and simulations

    Dosing regimen (mg/frequency/day) resulting in optimal PK/PD target attainment

    Time frame: Day 1, Day 2, Day 4, Day 6, Day 7, Day 8 and Day 10 of the study conduct

  6. Correlation between drug exposure and different parameters

    Correlation between drug exposure (AUC, Cl/F) and i. Viral elimination dynamics (elimination rate constant), including time to viral clearance (time to negative RT-PCR blood for Lassa virus), regression analysis of viral loads in function of time ii. Length of hospital stay: duration of hospitalization as defined by the enrollment date to discharged data iii. Number of deaths: mortality records iv. Blood component therapy use as concomittant medication

    Time frame: 10 days

  7. Co-variates impacting on drug exposure

    Co-variates impacting on drug exposure: demographices, biological, clinical and virologic data captured in patient case files and sources documents may be assessed as convariates on drug exposure

    Time frame: 10 days

07

Study locations

2 sites
  • Irrua Specialist Teaching Hospital
    Irrua, Edo State, Nigeria
  • Federal Medical Center of Owo
    Owo, Ondo State, Nigeria
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In line with the funding conditions, individual participant data (IPD) is to be shared. However, this will be de-identified IPD that used to generate the results reported (text, tables, figures and appendices). IPD sharing will begin after publication of primary results and will be available for a period which is aligned with the data sharing agreements approved by the research ethics committees of the counties/sites participating in the trial. The IPD shall be made available via a request and evaluation process to investigators whose proposed research has received IRB approval. All investigators to whom this IPD is made available will be required to be part of the execution of a data use agreement.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: From the time of publication and for a period which is aligned with the data sharing agreements approved by the research ethics committees of the counties/sites participating in the trial.

Access criteria: This IPD shall be made available via a request and evaluation process to investigators whose proposed research has received inistitutional review board (IRB) approval. All investigators to whom this IPD is made available will be required to be part of the execution of a data use agreement. The data shall be made available through a governed data access process which includes a transparent, accountability and decision-making process: Completion of data request form Evaluation by a data access committee Data sharing Agreement Secure transfer of data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Nov 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
Jun 1, 2021
StartActual
Jul 30, 2021
Primary completionActual
Nov 10, 2022
CompletionActual
Nov 17, 2022
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04907682
Lead sponsor
Bernhard Nocht Institute for Tropical Medicine
Collaborators
University of Hamburg-Eppendorf, Alliance for International Medical Action, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, Federal Medical Centre, Owo, Irrua Specialist Teaching Hospital
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Jul 30, 2021
Primary completion
Nov 10, 2022
Completion
Nov 17, 2022
Last update
Feb 8, 2023

Study contacts

Peter Akhideno, Dr
principal investigator · ISTH
Sylvanus Okogbenin, Prof
principal investigator · ISTH
Oluwafemi Ayodeji, Dr
principal investigator · FMCO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Favipiravir

Start the discussion